Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa

被引：0

作者：

Konen, Franz Felix ^{[1
]}

Pfeuffer, Steffen ^{[2
]}

Jendretzky, Konstantin Fritz ^{[1
]}

Gehring, Klaus ^{[3
]}

Elias-Hamp, Birte

Suehs, Kurt-Wolfram ^{[1
]}

Pawlitzki, Marc ^{[4
]}

Meuth, Sven ^{[4
]}

Kleinschnitz, Christoph ^{[5
,6
]}

Pul, Refik ^{[5
,6
]}

Skripuletz, Thomas ^{[1
]}

机构：

[1] Hannover Med Sch, Dept Neurol, Hannover, Germany

[2] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Neurol, Giessen, Germany

[3] Neurozentrum Klosterforst, Itzehoe, Germany

[4] Heinrich Heine Univ Duesseldorf, Univ Hosp Duesseldorf, Dept Neurol, Dusseldorf, Germany

[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany

[6] Ctr Translat Neuro & Behav Sci C TNBS, Essen, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P293/939

引用

页码：328 / 330

页数：3

共 50 条

[1] De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study
Sacco, Rosaria
Pravata, Emanuele
Disanto, Giulio
Mallucci, Giulia
Maceski, Aleksandra Maleska
Kuhle, Jens
Gobbi, Claudio
Zecca, Chiara
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 92
[2] Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Seze, Jerome
Maillart, Elisabeth
Gueguen, Antoine
Laplaud, David A. A.
Michel, Laure
Thouvenot, Eric
Zephir, Helene
Zimmer, Luc
Biotti, Damien
Liblau, Roland
FRONTIERS IN IMMUNOLOGY, 2023, 14
[3] Safety and efficacy of cladribine therapy following a treatment with anti-CD20 compounds in relapsing multiple sclerosis patients: a pilot study
Sacco, R.
Disanto, G.
Pravata, E.
Gobbi, C.
Zecca, C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 852 - 852
[4] Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review
Brown, Justin D.
Muston, Benjamin T.
Massey, Jennifer
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
[5] Chronic active MRI lesions in multiple sclerosis patients undergoing anti-CD20 antibody therapies
Ben Ayad, A.
Sellimi, A.
Wynen, M.
Bugli, C.
Mullins, W. A.
Kalaitzidis, G.
Lolli, V.
Perrotta, G.
El Sankari, S.
Duprez, T.
Beck, E. S.
Li, X.
van Pesch, V.
Calabresi, P. A.
Reich, D. S.
Absinta, M.
Maggi, P.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 476 - 477
[6] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
Vollmer, Brandi
Nair, Kavita
Corboy, John
Vollmer, Timothy
Alvarez, Enrique
NEUROLOGY, 2019, 92 (15)
[7] Switching patients with multiple sclerosis from anti-CD20 or S1P receptor modulators to cladribine tablets in the United States: A real-world age-based analysis
Kutz, Christen
Aldridge, Julie
Evans, Emily
Jackson, Leila
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1091 - 1091
[8] COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
Meca-Lallana, Virginia
Aguirre, Clara
Rio, Beatrizdel
Cardenoso, Laura
Alarcon, Teresa
Vivancos, Jose
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 44
[9] Retrospective analysis of multiple sclerosis patients who initiated oral cladribine more than 4 years ago - data from a German cladribine cohort
Ernst, Michael
Lara, Woitschach
Lukas, Cepek
Rau, Daniela
Schlemilch-Paschen, Sylke
Benedicta, Kuehnler
Kowarik, Markus
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 381 - 382
[10] Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study
Hua, Le
Brown, Brandon
Camacho, Elizabeth
Greenberg, Benjamin M.
Henry, Roland
Houtsma, Erik
Alvarez, Enrique
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1167 - 1168

← 1 2 3 4 5 →